Pages that link to "Q34625881"
Jump to navigation
Jump to search
The following pages link to An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms (Q34625881):
Displaying 50 items.
- Anaplastic lymphoma kinase: signalling in development and disease (Q24312329) (← links)
- Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors (Q24595585) (← links)
- Targeting the hepatocyte growth factor-cMET axis in cancer therapy (Q24606259) (← links)
- The MET axis as a therapeutic target (Q24609682) (← links)
- Clinical use of crizotinib for the treatment of non-small cell lung cancer (Q24630466) (← links)
- ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance (Q26775347) (← links)
- Clinical significance of MET in gastric cancer (Q26776190) (← links)
- The Evolution of Therapies in Non-Small Cell Lung Cancer (Q26786932) (← links)
- ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options (Q26820845) (← links)
- MET inhibitors in combination with other therapies in non-small cell lung cancer (Q26823203) (← links)
- ALK and ROS1 as a joint target for the treatment of lung cancer: a review (Q26851392) (← links)
- Emerging importance of ALK in neuroblastoma (Q26858819) (← links)
- Non-coding RNAs in lung cancer (Q26866521) (← links)
- Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer (Q27334957) (← links)
- c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations (Q27649203) (← links)
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) (Q27671432) (← links)
- Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy (Q27682798) (← links)
- EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer (Q27851440) (← links)
- Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen (Q27851681) (← links)
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations (Q27853138) (← links)
- Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling (Q27853157) (← links)
- Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping (Q27853167) (← links)
- Second- and third-generation ALK inhibitors for non-small cell lung cancer (Q28072496) (← links)
- Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK (Q28083446) (← links)
- FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase (Q28118071) (← links)
- Inhibitors of the anaplastic lymphoma kinase (Q28267124) (← links)
- Molecular pathogenesis of peripheral neuroblastic tumors (Q28271405) (← links)
- MET molecular mechanisms and therapies in lung cancer (Q28272688) (← links)
- Sustained proliferation in cancer: Mechanisms and novel therapeutic targets (Q28396388) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells (Q28553147) (← links)
- Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival (Q28833673) (← links)
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (Q29547693) (← links)
- Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition (Q30414265) (← links)
- Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy (Q30422676) (← links)
- The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma (Q30494514) (← links)
- MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents (Q30502341) (← links)
- Polypharmacology in Precision Oncology: Current Applications and Future Prospects (Q30846907) (← links)
- Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. (Q31062741) (← links)
- An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis (Q33588267) (← links)
- Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment (Q33607965) (← links)
- Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities (Q33636098) (← links)
- Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy (Q33652455) (← links)
- Efficacy of c-Met inhibitor for advanced prostate cancer (Q33718726) (← links)
- The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment (Q33769429) (← links)
- ALK-rearrangements and testing methods in non-small cell lung cancer: a review (Q33776835) (← links)
- Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction (Q33879009) (← links)
- Virtual screening and further development of novel ALK inhibitors (Q33880396) (← links)
- Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells (Q33984904) (← links)
- Small molecule c-Met kinase inhibitors: a review of recent patents (Q34094632) (← links)